Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Biosion Out-Licenses Siglec-15 mAb for Solid Tumors in $226 Million Pact

publication date: Mar 29, 2022

Nanjing Biosion out-licensed global rights (ex-China) to Pyxis Oncology for an immunotherapy aimed at solid tumor cancers in a $226 million agreement. BSI-060T, now known as PYX-106, is Biosion's anti-Siglec-15 mAb. The company will receive a $10 million up-front license fee, $216 million in milestones and royalties on commercial sales. Pyxis, which also has an opportunity to in-license other Biosion anti-Siglec-15 candidates, plans to submit an IND for PYX-106 in the US during Q2 of this year. More details....

Stock Symbols: (NSDQ: PYXS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here